Immune responses and protective efficacy of a recombinant swinepox virus expressing HA1 against swine H1N1 influenza virus in mice and pigs

Vaccine

Volumn 30, Issue 20, 2012, Pages 3119-3125

  Xu, Jiarong ^a   Huang, Dongyan ^a,b   Liu, shichao ^a   Lin, Huixing ^a   Zhu, Haodan ^a   Liu, Bao ^a   Lu, Chengping ^a  

^a NANJING AGRICULTURAL UNIVERSITY   (China)

^b JIANGXI AGRICULTURAL UNIVERSITY   (China)

Author keywords

Animal trial; Hemagglutinin; Immunogenicity; Protective efficacy; Recombinant swinepox virus; Swine H1N1 influenza virus

Indexed keywords

GAMMA INTERFERON; SWINE INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SUIPOXVIRUS; SWINE; SWINE INFLUENZA VIRUS; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SUIPOXVIRUS; SWINE; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 84862785610     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.028     Document Type: Article

References (46)

1. Wang T.T., Palese P. Unraveling the mystery of swine influenza virus. Cell 2009, 137(6):983-985.
2. Tang M., Harp J.A., Wesley R.D. Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2). Archives of Virology 2002, 147(11):2125-2141.
3. Ito T. Interspecies transmission and receptor recognition of influenza A viruses. Microbiology and Immunology 2000, 44(6):423-430.
4. Ito T., Couceiro J.N., Kelm S., Baum L.G., Krauss S., Castrucci M.R., et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. Journal of Virology 1998, 72(9):7367-7373.
5. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science (New York, NY) 2009, 325(5937):197-201.
6. Hghihghi H.R., Read L.R., Mohammadi H., Pei Y., Ursprung C., Nagy E., et al. Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus. Clinical and Vaccine Immunology 2011, 17(3):454-463.
7. Hessel A., Schwendinger M., Fritz D., Coulibaly S., Holzer G.W., Sabarth N., et al. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. PloS One 2011, 5(8):e12217.
8. Mayrhofer J., Coulibaly S., Hessel A., Holzer G.W., Schwendinger M., Bruhl P., et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of Virology 2009, 83(10):5192-5203.
9. Hessel A., Schwendinger M., Holzer G.W., Orlinger K.K., Coulibaly S., Savidis-Dacho H., et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PloS One 2011, 6(1):e16247.
10. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31(2 Pt 1):417-427.
11. Lubeck M.D., Gerhard W. Topological mapping antigenic sites on the influenza A/PR/8/34 virus hemagglutinin using monoclonal antibodies. Virology 1981, 113(1):64-72.
12. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289(5796):373-378.
13. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annual Review of Biochemistry 1987, 56:365-394.
14. Moorkamp L., Beineke A., Kaim U., Diesterbeck U., Urstadt S., Czerny C.P., et al. Swinepox-skin disease with sporadic occurrence. Dtsch Tierarztl Wochenschr 2008, 115(4):162-166.
15. van der Leek M.L., Feller J.A., Sorensen G., Isaacson W., Adams C.L., Borde D.J., et al. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63. The Veterinary Record 1994, 134(1):13-18.
16. Tripathy D.N. Swinepox virus as a vaccine vector for swine pathogens. Advances in Veterinary Medicine 1999, 41:463-480.
17. Lin H.X., Huang D.Y., Wang Y., Lu C.P., Fan H.J. A novel vaccine against Streptococcus equi ssp. zooepidemicus infections: the recombinant swinepox virus expressing M-like protein. Vaccine 2011, 29(40):7027-7034.
18. Manuel E.R., Wang Z., Li Z., La Rosa C., Zhou W., Diamond D.J. Intergenic region 3 of modified vaccinia Ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology 2011, 403(2):155-162.
19. Kutinova L., Hainz P., Ludvikova V., Maresova L., Nemeckova S. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus. Virology 2001, 280(2):211-220.
20. Tian Z.J., Zhou G.H., Zheng B.L., Qiu H.J., Ni J.Q., Yang H.L., et al. A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge. Veterinary Immunology and Immunopathology 2006, 111(3-4):211-218.
21. Wesley R.D., Tang M., Lager K.M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 2004, 22(25-26):3427-3434.
22. Sipo I., Knauf M., Fechner H., Poller W., Planz O., Kurth R., et al. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 2011, 29(8):1690-1699.
23. Kyriakis C.S., De Vleeschauwer A., Barbe F., Bublot M., Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 2009, 27(16):2258-2264.
24. Soprana E., Panigada M., Knauf M., Radaelli A., Vigevani L., Palini A., et al. Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene. Journal of Virological Methods 2011, 174(1-2):22-28.
25. Du Y., Li Y., He H., Qi J., Jiang W., Wang X., et al. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine. Journal of Virological Methods 2008, 149(1):144-152.
26. Manicassamy B., Medina R.A., Hai R., Tsibane T., Stertz S., Nistal-Villan E., et al. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathogens 2011, 6(1):e1000745.
27. Van Reeth K., Braeckmans D., Cox E., Van Borm S., van den Berg T., Goddeeris B., et al. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 2009, 27(45):6330-6339.
28. Larsen D.L., Karasin A., Zuckermann F., Olsen C.W. Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Veterinary Microbiology 2000, 74(1-2):117-131.
29. Heinen P.P., Rijsewijk F.A., de Boer-Luijtze E.A., Bianchi A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. The Journal of General Virology 2002, 83(Pt 8):1851-1859.
30. Masic A., Lu X., Li J., Mutwiri G.K., Babiuk L.A., Brown E.G., et al. Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. Vaccine 2011, 28(43):7098-7108.
31. Masic A., Booth J.S., Mutwiri G.K., Babiuk L.A., Zhou Y. Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs. Journal of Virology 2009, 83(19):10198-10210.
32. Jin H.S., Park E.K., Lee J.M., NamKoong S.E., Kim D.G., Lee Y.J., et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecologic Oncology 2005, 97(2):559-567.
33. Park E.K., Kim Y.W., Lee J.M., NamKoong S.E., Kim D.G., Chun H.J., et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity against human papillomavirus 16-associated tumor. Cancer Research and Treatment 2005, 37(1):63-70.
34. Fitzpatrick E.A., Avdiushko M., Kaplan A.M., Cohen D.A. Role of T cell subsets in the development of AIDS-associated interstitial pneumonitis in mice. Experimental Lung Research 1999, 25(8):671-687.
35. Purdy A., Case L., Duvall M., Overstrom-Coleman M., Monnier N., Chervonsky A., et al. Unique resistance of I/LnJ mice to a retrovirus is due to sustained interferon gamma-dependent production of virus-neutralizing antibodies. The Journal of Experimental Medicine 2003, 197(2):233-243.
36. Ryman K.D., White L.J., Johnston R.E., Klimstra W.B. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunology 2002, 15(1):53-76.
37. Chen H., Huang Q., Cui B., Li X., Guan Q. Construction of recombinant fowlpox virus coexpressing HA from subtype H5 of avian influenza virus and chicken interleukin-18. Wei sheng wu xue bao=Acta Microbiologica Sinica 2008, 48(8):1025-1030.
38. Weyer J., Rupprecht C.E., Nel L.H. Poxvirus-vectored vaccines for rabies-a review. Vaccine 2009, 27(51):7198-7201.
39. Jacobs B.L., Langland J.O., Kibler K.V., Denzler K.L., White S.D., Holechek S.A., et al. Vaccinia virus vaccines: past, present and future. Antiviral Research 2009, 84(1):1-13.
40. Veits J., Romer-Oberdorfer A., Helferich D., Durban M., Suezer Y., Sutter G., et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008, 26(13):1688-1696.
41. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. The Journal of Infectious Diseases 2007, 195(11):1598-1606.
42. Winslow B.J., Kalabat D.Y., Brown S.M., Cochran M.D., Collisson E.W. Feline B7.1 and B7.2 proteins produced from swinepox virus vectors are natively processed and biologically active: potential for use as nonchemical adjuvants. Veterinary Microbiology 2005, 111(1-2):1-13.
43. Barcena J., Blasco R. Recombinant swinepox virus expressing beta-galactosidase: investigation of viral host range and gene expression levels in cell culture. Virology 1998, 243(2):396-405.
44. Kreijtz J.H., Suezer Y., de Mutsert G., van Amerongen G., Schwantes A., van den Brand J.M., et al. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PloS One 2009, 4(11):e7790.
45. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. The Journal of Infectious Diseases 2009, 199(3):405-413.
46. Hahn J., Park S.H., Song J.Y., An S.H., Ahn B.Y. Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein. Journal of Virological Methods 2001, 93(1-2):49-56.